MDxHealth (MDXH) Corporate presentation summary

Growth fundamentals and market opportunity

• Clinical pathway expanded through acquisitions of Genomic Prostate Score and ExoDx Prostate Test, enhancing the prostate cancer diagnostic menu.

• U.S. addressable market estimated at $4.8B, with products covering elevated PSA, localized prostate cancer, and active surveillance.

• Over 500,000 patients tested, with established reimbursement and inclusion in clinical guidelines.

• Commercial team expanded to over 80, leveraging a broad KOL network and established brands.

• Additional growth opportunities include menu expansion and channel development outside urology.

Product portfolio and clinical evidence

• ExoDx is a non-invasive urine test for elevated PSA, requiring no DRE, with 91% NPV for clinically significant prostate cancer and guideline inclusion.

• Confirm mdx is an epigenetic test performed on biopsy tissue, offering 96% NPV for aggressive prostate cancer and potential cost savings.

• GPS mdx analyzes gene activity in localized prostate cancer, guiding treatment intensity and validated in multiple studies.

• Monitor mdx, in development, aims to provide a non-invasive alternative for active surveillance monitoring.

• All tests are supported by robust clinical evidence, with dozens of published validation and utility studies.

Financial performance and outlook

• Q2 2026 revenue grew 16% year-over-year to $27.2M; H1 2026 revenue up 14% to $51.1M.

• Gross profit margin declined slightly to 65.7% in Q2 2026; net loss increased to $9.5M.

• Adjusted EBITDA was negative for both Q2 and H1 2026, reflecting ongoing investment in growth.

• 2026 revenue guidance set at $110–115M, representing approximately 23% growth at the midpoint.

• Multi-billion-dollar market opportunity and expanded product menu position the company for sustainable growth.